The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114m In-mediated targeting therapy

By Tolmachev Vladimir  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, Iss. 9, 2009-09 ,pp. : 1460-1468

Springer Publishing Company

Access to resources Recommend Favorite

[¹⁸F]FBEM-Z_HER2:342–Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography

By Kramer-Marek Gabriela   Kiesewetter Dale   Martiniova Lucia   Jagoda Elaine   Lee Sang   Capala Jacek  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Iss. 5, 2008-05 ,pp. : 1008-1018

Springer Publishing Company

Access to resources Recommend Favorite

Development and preclinical characterisation of ^99mTc-labelled Affibody molecules with reduced renal uptake

By Ekblad Torun   Tran Thuy   Orlova Anna   Widström Charles   Feldwisch Joachim   Abrahmsén Lars   Wennborg Anders   Karlström Amelie   Tolmachev Vladimir  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Iss. 12, 2008-12 ,pp. : 2245-2255

Springer Publishing Company

Access to resources Recommend Favorite

HER2 Testing Recommendations in Australia

By Bilous Michael  

Pathology, Vol. 33, Iss. 4, 2001-11 ,pp. : 425-427

Ashgate Publishing Ltd

Access to resources Recommend Favorite

An In Vivo Method for Using 5-Bromo-2'-deoxyuridine (BrdU) as a Marker of Chemically-Induced Hepatocellular Proliferation in the Japanese Medaka (Oryzias latipes)

By Brennan Linda M.   Boncavage-Hennessey E. Maxine   Wolfe Marilyn J.   Toussaint Margaret W.   Dennis William E.   Rosencrance Alan B.   Gardner Henry S.  

Toxicologic Pathology, Vol. 29, Iss. 3, 2001-05 ,pp. : 387-397

Ashgate Publishing Ltd

Access to resources Recommend Favorite